The COVID-19 pandemic has disrupted most industry, business and daily life, and clinical investigational sites are no exception. Worldwide, various sources report slowdowns, delays or even cancellations of clinical trials, costing industry sponsors as of yet not calculated losses. At the site level, concerns have skyrocketed by 124% in just one week from 25% to 56%, according to a recent survey, due to concerns of COVID-19 related interruptions to recruitment and retention for clinical trials. With the disease now accelerating through America, sites will experience further delays, and sponsors may need to put even more trials on hold or even cancel them.
The ongoing site survey is produced by an Illinois patient recruitment and retention firm called Continuum Clinical.